Revvity, Inc. (0KHE.L) Bundle
A Brief History of PerkinElmer, Inc.
PerkinElmer, Inc. was founded in 1937 by Richard Perkin and Charles Elmer in Los Angeles, California. Initially, the company focused on selling scientific instruments and expanded its offerings to include analytical instruments and diagnostics solutions.
In 1961, PerkinElmer became a publicly traded company on the NYSE under the symbol PKI. By the late 1970s, PerkinElmer had established a strong presence in photonics and analytical instrumentation. The company’s commitment to innovation was demonstrated when it introduced the first commercial infrared spectrometers.
Throughout the 1980s and 1990s, PerkinElmer continued to expand its product offerings and entered new markets. Notably, in 1993, the company acquired the assets of the dissolved company, Analytical Technologies, which strengthened its product line in the field of molecular analysis.
In 2000, PerkinElmer made a strategic shift towards life sciences, acquiring the Life Sciences division of Wallac, a Finnish company, broadening its capabilities in genomics and drug discovery.
By 2010, the company had started to focus more intently on health and diagnostics, culminating in a pivotal acquisition in 2011 when it acquired Caliper Life Sciences for approximately $300 million. This acquisition enhanced PerkinElmer’s portfolio in molecular and cellular biology.
In 2016, PerkinElmer announced its acquisition of Quad Technologies, a provider of bioprocessing products, further solidifying its position within the biotechnology sector.
As financial performance demonstrates, in 2022, PerkinElmer reported revenues of approximately $3.6 billion, reflecting a year-over-year growth of 6.9%. The company’s net income for the same period was around $490 million, translating to a diluted earnings per share (EPS) of $3.60.
Below is a table summarizing key financial metrics and acquisitions by PerkinElmer over critical periods:
| Year | Revenue ($ billion) | Net Income ($ million) | EPS ($) | Key Acquisition |
|---|---|---|---|---|
| 2011 | 1.75 | 180 | 1.24 | Caliper Life Sciences ($300 million) |
| 2016 | 2.56 | 340 | 2.50 | Quad Technologies |
| 2020 | 3.45 | 586 | 4.07 | None |
| 2022 | 3.60 | 490 | 3.60 | None |
In 2023, PerkinElmer announced a rebranding initiative aimed at enhancing its focus on human health and sustainability. This strategic pivot is reflected in its ongoing commitment to innovation and customer-centric solutions.
Currently, PerkinElmer operates in over 150 countries, with a workforce of more than 14,000 employees. The company has positioned itself as a leader in the diagnostic and life sciences industry, continually adapting to emerging trends and technological advancements.
A Who Owns PerkinElmer, Inc.
PerkinElmer, Inc. is a publicly traded company listed on the New York Stock Exchange under the ticker symbol PKI. As of October 2023, the company has a market capitalization of approximately $11.5 billion.
Ownership of PerkinElmer is distributed among institutional investors, individual shareholders, and company executives. The latest data shows that institutional ownership accounts for about 90% of the total shares outstanding, while insiders hold around 2%.
Major Institutional Shareholders
| Institution | Ownership (%) | Number of Shares |
|---|---|---|
| Vanguard Group Inc. | 8.5% | 6.5 million |
| BlackRock Inc. | 7.2% | 5.5 million |
| Wellington Management Group LLP | 5.1% | 3.9 million |
| State Street Global Advisors | 4.8% | 3.6 million |
| Invesco Ltd. | 3.9% | 3.0 million |
As of the most recent proxy statement, the top five institutional shareholders combined own approximately 29.5% of the total shares, highlighting significant institutional interest in the company. Individual or retail investors make up the remaining ownership percentages.
Executive Ownership
Executive officers and board members of PerkinElmer also hold a stake in the company. The CEO, Prahlad Singh, has reported beneficial ownership of approximately 0.5% of the company's shares. Other key executives also have minor holdings, which collectively account for the 2% held by insiders.
Recent Stock Performance
As of October 2023, PerkinElmer's stock is trading at around $90 per share. The company has experienced a year-to-date performance of approximately 15%. Over the last five years, the stock has seen a compound annual growth rate (CAGR) of 10%.
Market Trends and Analysis
The ownership landscape of PerkinElmer reflects broader trends in the healthcare and diagnostics sector. Institutional investors are increasingly focusing on companies that provide essential products and services, driving up interest in PerkinElmer due to its role in diagnostic instrumentation and reagents.
Furthermore, PerkinElmer's acquisition strategy has bolstered its portfolio, with significant transactions over the past few years. In 2021, the acquisition of BioLegend for about $5.25 billion marked a strategic move to enhance its capabilities in the life sciences sector.
Conclusion of Ownership Structure
The ownership of PerkinElmer, Inc. is primarily characterized by institutional investors. Their combined shareholding illustrates confidence in the company’s growth prospects and market positioning within the diagnostics and life sciences fields.
PerkinElmer, Inc. Mission Statement
PerkinElmer, Inc. is a global leader in the fields of diagnostics, life sciences, and environmental testing. The company’s mission statement emphasizes their commitment to innovating and providing high-quality products and solutions that improve patient health, enhance productivity in laboratories, and ensure the safety and quality of the environment.
The mission centers on several key principles:
- To deliver innovative solutions that drive the detection and treatment of disease.
- To empower scientists and researchers with advanced instruments and technologies.
- To operate responsibly and sustainably, contributing to the well-being of communities.
- To foster a culture of continuous improvement and exceptional customer service.
As part of its operational framework, PerkinElmer emphasizes sustainability and corporate responsibility, aiming to meet the needs of customers while advancing a healthier world. The financial performance of the company reflects its alignment with its mission.
| Year | Revenue (in millions) | Net Income (in millions) | EPS (Earnings Per Share) | R&D Expenses (in millions) |
|---|---|---|---|---|
| 2022 | $3,030 | $406 | $3.30 | $256 |
| 2021 | $2,676 | $630 | $4.92 | $228 |
| 2020 | $2,540 | $566 | $4.18 | $196 |
| 2019 | $2,416 | $473 | $3.62 | $181 |
PerkinElmer's focus on innovation is reflected in its substantial investment in R&D, with **$256 million** spent in 2022, representing approximately **8.5%** of total revenue. This dedication to research and development is pivotal in enhancing their product offerings and meeting the evolving needs of the healthcare and environmental sectors.
In addition to its financial metrics, PerkinElmer has expanded its portfolio through strategic acquisitions, including the purchase of BioLegend in 2022 for approximately **$5.25 billion**. This acquisition was aimed at broadening its capabilities in the life sciences segment, reinforcing its mission to provide comprehensive solutions for scientists around the globe.
Furthermore, PerkinElmer has reported a year-over-year revenue growth rate of **13.2%** from 2021 to 2022, indicating a robust demand for its diagnostics and life sciences products. This growth aligns with the increasing need for advanced diagnostic tools, particularly in the wake of global health challenges.
The company's commitment to sustainability is evident in its operational practices, which aim to minimize waste and energy consumption. PerkinElmer has set goals to reduce greenhouse gas emissions by **30%** by 2025, further showcasing its dedication to corporate social responsibility.
Overall, PerkinElmer's mission statement is not just a declaration of intent but a guiding principle that shapes its strategic planning, financial performance, and commitment to the community and environment. This approach not only drives growth but also positions the company as a leader in the global market for diagnostics and life sciences solutions.
How PerkinElmer, Inc. Works
PerkinElmer, Inc. is a global leader in the fields of diagnostics, life sciences, and applied markets, providing pivotal technology and services to enhance human and environmental health. The company operates through two main segments: Diagnostics and Life Sciences.
Diagnostics Segment
The Diagnostics segment focuses on providing comprehensive solutions for the detection and diagnosis of diseases. This includes products related to newborn screening, infectious disease testing, and molecular diagnostics.
In the fiscal year 2022, the Diagnostics segment generated approximately $1.3 billion in revenue, indicating a year-over-year growth of 11% compared to 2021.
Life Sciences Segment
The Life Sciences segment provides essential tools and services for research and development in the pharmaceutical, biotechnology, and academic sectors. This segment covers areas such as drug discovery, genomics, and laboratory services.
For the fiscal year 2022, the Life Sciences segment reported revenues of around $1.05 billion, which reflects a growth of 7% over the previous year.
Market Position and Strategy
PerkinElmer has positioned itself as a vital contributor in the diagnostics market, especially with its innovations in molecular and infectious disease testing. The company's strategic focus includes:
- Investing in research and development to enhance product offerings.
- Acquiring complementary technologies and companies to expand its market reach.
- Forming partnerships with healthcare providers to integrate diagnostics into patient care.
Financial Performance Overview
| Fiscal Year | Total Revenue | Diagnostics Revenue | Life Sciences Revenue | Net Income |
|---|---|---|---|---|
| 2022 | $2.35 billion | $1.3 billion | $1.05 billion | $340 million |
| 2021 | $2.1 billion | $1.17 billion | $920 million | $313 million |
| 2020 | $1.9 billion | $1.05 billion | $850 million | $270 million |
Recent Developments
In recent months, PerkinElmer has launched several new platforms and technologies aimed at enhancing diagnostic capabilities. Notable advancements include:
- The introduction of the "GSP" technology for genomic sequencing, which improves accuracy and speed.
- Expansion of its immunodiagnostic solutions portfolio, targeting infectious disease markets.
- Strategic acquisitions, including the recent purchase of a molecular diagnostics company for $150 million, aimed at broadening its capabilities in personalized medicine.
Stock Performance
PerkinElmer's stock is traded on the New York Stock Exchange under the ticker symbol "PKI." As of October 2023, the stock price stands at approximately $90 per share, with a market capitalization of around $10 billion.
The stock has shown resilience, with a year-to-date increase of approximately 15%, outperforming the S&P 500 index which has increased by about 10% during the same period.
Investment Outlook
Analysts remain optimistic about PerkinElmer's future growth prospects, especially in the context of ongoing global health challenges and an increasing focus on personalized medicine. The consensus target price for the stock is around $100, reflecting potential upside from current levels.
Conclusion on Operational Efficiency
PerkinElmer has streamlined its operations through cost management initiatives which have led to an improvement in operational efficiency. The company’s operating margin for 2022 stood at 14.5%, up from 13.5% in 2021.
How PerkinElmer, Inc. Makes Money
PerkinElmer, Inc. operates primarily through two segments: Discovery & Analytical Solutions and Diagnostics. The company generates revenue through the sale of scientific instruments, consumables, and software, as well as related services.
Revenue Breakdown
For the full year ending December 31, 2022, PerkinElmer reported total revenues of $3.5 billion. The revenue from each segment was as follows:
| Segment | Revenue (2022) | Percentage of Total Revenue |
|---|---|---|
| Discovery & Analytical Solutions | $1.8 billion | 51.4% |
| Diagnostics | $1.7 billion | 48.6% |
Key Revenue Sources
The Discovery & Analytical Solutions segment focuses on areas such as:
- Life Sciences
- Environmental Testing
- Food Safety Testing
- Clinical Research
In 2022, the Life Sciences sub-segment contributed approximately $1.2 billion, driven by sales of instruments and reagents used for drug discovery and development. Environmental testing and food safety accounted for around $400 million each, bolstered by regulatory demands and the growing focus on sustainable practices.
In the Diagnostics segment, key offerings included:
- Genetic testing solutions
- Infectious disease testing
- Immunodiagnostics
The infectious disease testing market experienced significant growth during the pandemic, with revenue reaching approximately $900 million in 2022. Genetic testing solutions provided an additional $600 million in revenue.
Service Revenue
PerkinElmer has also emphasized recurring revenue through service contracts. In 2022, service revenue accounted for approximately $900 million, representing about 25.7% of total revenue. This recurring stream is critical for maintaining long-term relationships with clients and ensuring steady cash flow.
Market Trends and Future Outlook
The demand for diagnostic and analytical solutions continues to grow, driven by advancements in technology and increased focus on health and safety. The global market for laboratory diagnostics is expected to grow at a compound annual growth rate (CAGR) of approximately 6.5% from 2023 to 2028, reaching an estimated $67 billion by 2028.
Additionally, the life sciences tools market is projected to grow to approximately $85 billion by 2026, at a CAGR of around 8%. PerkinElmer’s investments in innovation and strategic acquisitions are aimed at positioning the company to capitalize on these growing markets.
Strategic Acquisitions
In 2021, PerkinElmer acquired BioLegend, a leading provider of antibodies and reagents for life sciences research, for approximately $5.3 billion. This acquisition strengthened PerkinElmer’s portfolio in immunology and expanded its market reach significantly.
In 2022, the company also acquired Abcam's bio-pharma assets, adding complementary technologies to its existing offerings, further reinforcing its capabilities in the life sciences market.
Through strategic acquisitions, diverse revenue streams, and a strong focus on innovation, PerkinElmer, Inc. continues to navigate the evolving landscape of life sciences and diagnostics effectively.
Revvity, Inc. (0KHE.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.